Is the Outcome of Sars-Cov-2 Associated Guillain-Barre Syndrome at Variance Between Rich and Poor?

We read with interest the article by Nigatu et al. about a 70 years old male who developed quadruparesis and respiratory failure requiring intubation and mechanical ventilation one week after onset of mild COVID-19 [1]. The patient was tested positive for SARS-CoV-2 and diagnosed with Guillain-Barre syndrome (GBS) based upon the clinical presentation, nerve conduction studies (NCSs) and cerebrospinal fluid (CSF) investigations [1]. The patient was treated with glucocorticoids and achieved an incomplete recovery at the last follow-up three weeks after admission [1]. It was concluded that early identification and management of SARS-CoV-2 associated GBS (SC2aG) can improve the clinical outcome and that screening for SARS-CoV-2 in patients presenting with GBS is warranted. The study is appealing but raises concerns that need to be discussed.